Spruce Street Capital LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0002050194

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q2 2026 · 30 positions · Total reported value $509.68M · Top-10 concentration 70.2% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 21.1% · 8 new · 0 cut · 0 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -10.9% · vs SPY -13.0% · Prev Value $509.68M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -0.4% · vs SPY -2.5% · Latest Value $628.98M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q2 2026 13F filing, Spruce Street Capital LP disclosed 30 equity positions with a combined reported value of $509.68M. The filing implies a focused portfolio: its ten largest positions account for 70.2% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were KNSA ($58.71M), RLAY ($55.83M), LBRX ($44.66M). By sector, the heaviest allocations are Health Care 97.5%, Financials 2.5%. Versus the prior quarter, allocation shifted toward Health Care (+7.8pp), Financials (+1.2pp) and away from Other (-9.0pp).

Versus the prior quarter, Spruce Street Capital LP opened 8 new positions, trimmed 0 and fully exited 0, a turnover rate of 21.1% of positions. The portfolio's overlap with the prior quarter was 76% of names.

The largest new positions opened in Q2 2026 were IFRX ($11.99M), RACC ($5.35M), ZLAB ($5.30M).

Of the 3 positions fully exited versus the prior quarter, the largest were CNTA ($19.46M), KALV ($18.07M), MAZE ($5.97M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • IFRX INFLARX NV · $11.99M
  • RACC RESEARCH ALLIANCE CORP III · $5.35M
  • ZLAB ZAI LAB LTD · $5.30M
  • ACHV ACHIEVE LIFE SCIENCE INC · $4.81M
  • JATT JATT II ACQUISITION CORP · $1.82M

Fully Exited (vs previous quarter)

  • CNTA CENTESSA PHARMACEUTICALS PLC · prev qtr: $19.46M
  • KALV KALVISTA PHARMACEUTICALS INC · prev qtr: $18.07M
  • MAZE MAZE THERAPEUTICS INC · prev qtr: $5.97M

Insider Transactions (Form 4)

Latest Spruce Street Capital LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Spruce Street Capital LP is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 30 US equity positions with a combined value of $509.68M. HoldingsHub carries 3 quarters of its filings (Q4 2025–Q2 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-132577 (status: Approved), registered 2025-04-28
  • Regulatory AUM (Form ADV): $555.90M as of 2026-03-02
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 3 private funds, of which 3 hedge funds

Portfolio Structure

  • 30 positions · $509.68M reported value (Q2 2026)
  • Top 10 holdings = 70.2% of reported value
  • Largest position: KNSA (KINIKSA PHARMACEUTICALS INTL P ORD SHS CL A) at 11.5%
  • Average position size: $16.99M

Sector Tilt

  • Health Care 97.5%
  • Financials 2.5%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 5 new, 8 added, 1 reduced, 3 exited
  • 16 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: Spruce Street Capital LP appears to maintain a cautious and selective approach in their rebalancing. Their focus on Health Care sector indicates a belief in the potential for growth within this area, though the mix of adding and reducing positions suggests a conservative stance. 2. Key Moves: - Added: KINIKSA PHARMACEUTICALS INTL (KNSA), RELMADA THERAPEUTICS INC (RLMD), ALTO NEUROSCIENCE INC COM SHS (ANRO), ALKERMES PLC (ALKS), SAVARA INC (SVRA), VAXCYTE INC (PCVX). The largest additions were to KNSA and RLMD, indicating a significant interest in these companies. - Reduced: DIANTHUS THERAPEUTICS INC (DNTH) by 4.9%. - Held: Positions in RELAY THERAPEUTICS INC (RLAY), LB PHARMACEUTICALS INC (LBRX), ENLIVEN THERAPEUTICS INC (ELVN) were maintained. 3. Portfolio Structure: - Passive/Active: The fund seems to be active, as it is making strategic changes to its holdings. - Sector Bias: The Health Care sector is the primary focus, with a significant allocation to biotechnology and pharmaceutical companies. - Risk Appetite: The risk appetite is moderate, as the fund is adding to some positions but also reducing others, indicating a balanced approach. 4. Per-Holding One-Liner: - KNSA: KINIKSA PHARMACEUTICALS INTL - Developing novel therapies for rare and orphan diseases. - RLAY: RELAY THERAPEUTICS INC - Focused on developing treatments for neurological disorders. - LBRX: LB PHARMACEUTICALS INC - Specializes in the development of novel cancer therapies. - RLMD: RELMADA THERAPEUTICS INC - Developing treatments for neurodegenerative diseases. - ANRO: ALTO NEUROSCIENCE INC COM SHS - Developing therapies for neurological conditions. - DNTH: DIANTHUS THERAPEUTICS INC - Focused on cancer immunotherapy. - ALKS: ALKERMES PLC - Specializes in central nervous system (CNS) disorders. - SVRA: SAVARA INC - Developing treatments for rare genetic disorders. - PCVX: VAXCYTE INC - Developing live-attenuated vaccines. - ELVN: ENLIVEN THERAPEUTICS INC - Developing therapies for cardiovascular diseases. 5. One-Sentence Style Summary: Spruce Street Capital LP's Q2 2026 rebalancing reflects a conservative, sector-focused approach with a preference for Health Care, particularly biotechnology and pharmaceuticals, while maintaining a balanced portfolio through strategic additions and reductions.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 97.5%
Financials 2.5%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 918.07K $58.71M 11.52%
11.52%
Add
2 2.98M $55.83M 10.95%
10.95%
Hold
3 1.38M $44.66M 8.76%
8.76%
Hold
4 6.39M $44.23M 8.68%
8.68%
Add
5 1.35M $35.71M 7.01%
7.01%
Add
6 354.82K $34.59M 6.79%
6.79%
Reduce
7 543.88K $28.50M 5.59%
5.59%
Add
8 3.45M $21.27M 4.17%
4.17%
Add
9 306.05K $17.79M 3.49%
3.49%
Add
10 329.01K $16.70M 3.28%
3.28%
Hold
11 1.09M $15.87M 3.11%
3.11%
Add
12 3.69M $12.60M 2.47%
2.47%
Add
13 5.35M $11.99M 2.35%
2.35%
New
14 432.04K $11.21M 2.20%
2.20%
Hold
15 392.57K $11.05M 2.17%
2.17%
Hold
16 4.06M $9.94M 1.95%
1.95%
Hold
17 1.66M $9.19M 1.80%
1.80%
Hold
18 2.20M $8.57M 1.68%
1.68%
Hold
19 1.66M $8.04M 1.58%
1.58%
Hold
20 422.54K $7.74M 1.52%
1.52%
Hold
21 3.58M $7.27M 1.43%
1.43%
Hold
22 500.00K $5.35M 1.05%
1.05%
New
23 500.00K $5.32M 1.04%
1.04%
Hold
24 279.11K $5.30M 1.04%
1.04%
New
25 736.64K $4.81M 0.94%
0.94%
New
26 928.59K $4.32M 0.85%
0.85%
Hold
27 2.10M $4.22M 0.83%
0.83%
Hold
28 393.70K $3.62M 0.71%
0.71%
Hold
29 231.59K $3.46M 0.68%
0.68%
Hold
30 160.00K $1.82M 0.36%
0.36%
New

FAQ

What did Spruce Street Capital LP buy in 2026-Q2?

In its 2026-Q2 13F filing, Spruce Street Capital LP reported 30 equity positions worth $509.68M in aggregate; its largest disclosed positions were KNSA ($58.71M), RLAY ($55.83M), LBRX ($44.66M).

How large is Spruce Street Capital LP's portfolio?

Spruce Street Capital LP reported $509.68M of long equity holdings across 30 positions as of 2026-Q2. Top-10 holdings account for 70.2% of reported value.

What is Spruce Street Capital LP's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/spruce-street-capital/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →